Community screening with blood biomarkers for Alzheimer's in older adults
Official title: Stratified Screening of Blood Biomarkers for Alzheimer's Disease: a Prospective, Real World, Community-based Study
Run by Shanghai Fengxian District Central Hospital · NCT07570719 · Data updated 2026-11-12
This project will test whether two blood biomarkers (pTau217/Aβ42 ratio and GFAP) can detect Alzheimer's disease or mild cognitive impairment in community-dwelling older adults.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 60 Years to 80 Years |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Shanghai Fengxian District Central Hospital Academic / other |
| Locations | 4 sites (Shanghai, Shanghai Municipality and 3 other locations) |
| Status | Recruiting |
| Started | May 27, 2026 |
| Main results expected | March 31, 2027 |
| Study ends | March 31, 2028 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT07570719 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are community-dwelling adults aged 60–80 who can communicate normally and complete questionnaires and who do not meet the listed exclusion criteria.
✕Probably not a fit
People with severe mental disorders, major sensory or mobility impairments, severe organ failure or specific MRI abnormalities, current anticoagulant use, or those already enrolled in other interventional studies are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, multicenter observational cohort will enroll adults aged 60–80 from three Shanghai community health centers during routine physical examinations and outpatient visits. All participants will undergo blood testing for pTau217/Aβ42 ratio and GFAP, and those with abnormal results will complete a full cognitive test battery. The study will establish baseline population levels and reference intervals for these biomarkers in Chinese older adults and measure their screening performance in a real-world community setting. No study-specific interventions are administered; the protocol observes participants and records clinical and biomarker data.
Why it matters
Potential benefit: If successful, this work could enable earlier, less invasive identification of people at risk for Alzheimer's and provide normative biomarker ranges for Chinese older adults to guide referral and follow-up.
How similar studies have gone: Prior research shows plasma pTau217 and GFAP correlate with Alzheimer's pathology and are promising biomarkers, but their performance for community-based screening and in Chinese population cohorts remains under validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 60-80 years * Capable of normal communication and able to complete the questionnaire Exclusion Criteria: * Severe mental disorders * Severe visual, auditory, comprehension or mobility impairments * Current participation in other health intervention clinical studies * Severe renal insufficiency, heart failure, cerebrovascular disease, anemia, hyperthyroidism, hypothyroidism * Multiple cerebral infarctions, severe white matter hyperintensities, history of cerebral hemorrhage, current anticoagulant use, MRI abnormalities (cortical iron deposition, cerebral contusion) * Unable to comply with study procedures with no legal guardian
Where it's running
-
Fengcheng Community Health Service Center
Shanghai, Shanghai Municipality, China Recruiting -
Fengpu Community Health Service Center
Shanghai, Shanghai Municipality, China Recruiting -
Qingcun Community Health Service Center
Shanghai, Shanghai Municipality, China Recruiting -
Xidu Community Health Service Center
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Xiaojun Kuang, PhD
- Email: xj_kuang@126.com
- Phone: 021-57426172
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InRAD international registry for Alzheimer's disease and related dementias
This project will collect routine medical information over time to see how Alzheimer's disease, mild cognitive impairment, and related dementias progress and how current treatments are tolerated in adults.
-
Rural Veterans and Care Partners Walking Program
A virtual walking program is tested to see if it can help Veterans with mild cognitive impairment and their care partners in rural areas walk more each day.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Aging Brain Health Initiative in Fujian
This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.
-
See if multimodal biomarkers can map changes from mild cognitive impairment to dementia
This observational study tests whether clinical, blood, and brain-imaging markers can tell apart stages of cognitive decline and predict progression from mild cognitive impairment to dementia in about 600 people.
-
LIFU to Help Sleep and Amyloid Reduction in Older Adults with Cognitive Impairment
A wearable ultrasound device (ATTN201) is being tested to see if it’s safe and easy to use for people 65 and older with mild cognitive impairment and amyloid buildup.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.